Back to Stock Dashboard
Sector:
Healthcare
Add to portfolio
EVAX
Evaxion Biotech AS
CAPPED RATING
Evaxion Biotech AS (EVAX) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (C+); its weakest is Growth (D).
Quantitative Factor Evaluation • Updated
Overall Rating
2.2
/ 5.0
C
Value
C+
Factor Score
2.7
/ 5.0
Growth
D
Factor Score
1.3
/ 5.0
Profitability
C+
Factor Score
2.8
/ 5.0
Momentum
C
Factor Score
2.4
/ 5.0
Revisions
C-
Factor Score
1.9
/ 5.0
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
P/E Ratio
0.0
EV / EBITDA
-0.6
Rev Growth YoY
-100.0%
Gross Margin
N/M
Price Return 3M
-35.4%
Price Return 12M
13.0%
Catalyst Signal
0.00
Market Cap
N/A
TTM Revenue
N/A
Price / Sales
3.3
ROE
-82.9%
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-08-05 | C+ (2.7) | D (1.3) | C+ (2.8) | C (2.4) | C- (1.9) | C (2.2) |
| 2026-08-04 | C+ (2.7) | D (1.3) | C+ (2.8) | C (2.4) | C- (1.9) | C (2.2) |
| 2026-08-03 | C+ (2.7) | C- (2.0) | C+ (2.6) | C (2.4) | C- (2.0) | C (2.4) |
| 2026-08-02 | C+ (2.7) | C- (2.0) | C+ (2.6) | C (2.4) | C- (1.9) | C (2.3) |